摘要
Abstract
Objective To evaluate the treatment of telbivudine compared with lamivudine on chronic hepatitis B patients in china. Methods The papers were searched from April 2007 to August 2010 in the database of wanfangdata, CQVIP and CBM according to inclusion criteria and exclusion criteria. The selected six randomized controlled trials (RCT) findings were analysed by RevMan5.0.2 Software. Results Compared with the control group, telbivudine improved HBV.DNA negative rate,HBeAg negative rate.HBeAg seroconversion rate and ALT normalization rate more significant than those of lamivudine: RR were 1.39[95% CI( 1.26～1.54) ,Z =6.45 ,P <0.00001 ] ,1.46[95% CI( 1. 16～1.84),Z = 3.24,P=0.001],1.47[95%CI(1.12~1.92),Z = 2.77,P=0.006] and 1.15[95%CI(1.09 - 1. 22) ,Z=4. 88,P < 0.00001 ] ; Telbivudine can reduce the rate of drug resistance: OR is 0.31 [95% CI(0.20 ~0.48) ,Z =5.15 ,P <0.00001 ] ;There was no significant difference of the adverse events[OR = \.36,95%CI(0.84 ～2.20) ,Z = 1.27,P=0.20]. Conclusion Telbivudine is more effective in the HBV DNA reduction, increase of serum HBeAg negative rate, conversion rate and ALT normalization rate, with lower resistance rate and without increasing drug adverse reactions compared with lamivudine.关键词
肝炎,乙型,慢性/替比夫定/拉米夫定/Meta分析Key words
hepatitis B, chronic/ telbivudine/lamivudine/meta-analysis分类
医药卫生
